Biocon is trading at RS. 314.95, up by 9.75 points or 3.19% from its previous close of RS. 305.20 on the BSE.

The stock opened at RS. 322.25 and has touched a high and low of RS. 322.25 and RS. 313.75 respectively. So far, 1,09,391 shares have been traded on the counter.

Classified under the BSE group 'A', the stock has a face value of RS. 5 and has recorded a 52-week high of RS. 404.60 on January 21, 2025, and a 52-week low of RS. 260.00 on April 19, 2024. Over the past week, the stock traded between RS. 345.00 and RS. 295.30. The company's current market capitalization stands at RS. 37,884.93 crore.

Promoter holding in Biocon stands at 60.64%, while institutional investors hold 21.02% and non-institutional investors hold 18.34%.

In a key development, Biocon’s wholly-owned subsidiary, Biocon Pharma, has received approval from the U.S. Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Everolimus Tablets. The approval covers strengths of 0.25 mg, 0.5 mg, 0.75 mg, and 1 mg.

Everolimus is prescribed for the prophylaxis of organ rejection in adult patients, particularly in kidney and liver transplantation. This regulatory approval strengthens Biocon’s portfolio of complex, vertically integrated drug products.

Biocon is India’s largest and Asia’s leading biotechnology company, with a focus on biopharmaceuticals and research services. It is an innovation-driven enterprise committed to providing affordable treatment solutions for chronic diseases to patients worldwide.